China

Chinese Immuno-Oncology Company to Raise $282 Million Via Hong Kong IPO
Chinese Immuno-Oncology Company to Raise $282 Million Via Hong Kong IPO
CP Wire
CStone Pharmaceuticals
IPOs
China
Hong Kong
immuno-oncology
Flag link:
China to Cut Value Added Tax on Rare Disease Drugs to 3%
China to Cut Value Added Tax on Rare Disease Drugs to 3%
CP Wire
China
Rare Diseases
VAT
Flag link:
China to Cut Value Added Tax on Rare Disease Drugs to 3%
China
Flag link:
Rubio report outlines Chinese threat to U.S. biotech industry
Rubio report outlines Chinese threat to U.S. biotech industry
BioCentury
China
biotech
biosimilars
Marco Rubio
Flag link:
HaiHe raises $147M to advance cancer candidates
HaiHe raises $147M to advance cancer candidates
BioCentury
Shanghai HaiHe Biopharma
China
cancer
Flag link:
PhRMA urges USTR to address Japan's 'damaging' pricing policy, commends China's progress
PhRMA urges USTR to address Japan's 'damaging' pricing policy, commends China's progress
BioCentury
PhRMA
Japan
China
Flag link:
Indivior to Sell Rights in China for $122 Million
Indivior to Sell Rights in China for $122 Million
CP Wire
China
Indivior
Pukang
Flag link:
Pfizer launches China's first pay-for-performance model for cancer
Pfizer launches China's first pay-for-performance model for cancer
BioCentury
Pfizer
China
breast cancer
palbociclib
pay-for-performance
Flag link:
Merck KGaA signs China digital health deal with Tencent
Merck KGaA signs China digital health deal with Tencent
Pharmaforum
Merck KGaA
Tencent
China
digital healthcare
artificial intelligence
Flag link:
Boehringer building out biologics manufacturing in China
Boehringer building out biologics manufacturing in China
BioPharma Dive
China
drug manufacturing
Boehringer Ingelheim
biologics
Flag link:
In a first, China’s BeiGene scores FDA ‘breakthrough’ status for BTK inhibitor — potential rival for Imbruvica
In a first, China’s BeiGene scores FDA ‘breakthrough’ status for BTK inhibitor — potential rival for Imbruvica
Endpoints
China
FDA
Btk inhibitors
BeiGene
cancer
Flag link:
Celgene invests in Chinese biotech Antengene again
Celgene invests in Chinese biotech Antengene again
Fierce Biotech
Celgene
Antengene
China
Flag link:
US loses, EU wins as Chinese biotech investment shifts focus
US loses, EU wins as Chinese biotech investment shifts focus
Pharmaforum
China
Europe
biotech
Flag link:
3 China biotech stories to watch in 2019
3 China biotech stories to watch in 2019
Stat
China
biotech
Flag link:
New Pfizer CEO's top priorities? Think China and pipeline, not deals: analyst
New Pfizer CEO's top priorities? Think China and pipeline, not deals: analyst
Fierce Pharma
Pfizer
Pharma CEOs
Albert Bourla
Ian Read
China
Flag link:
WuXi AppTec prices Hong Kong offering in stormy market
WuXi AppTec prices Hong Kong offering in stormy market
BioCentury
China
Hong Kong
WuXi AppTec
Flag link:
China approves Descovy, Harvoni, Hemlibra
China approves Descovy, Harvoni, Hemlibra
BioCentury
China
Harvoni
Descovy
Hemlibra
Roche
Gilead Sciences
Flag link:
Pfizer strikes deal with Chinese online pharmacy Jianke
Pfizer strikes deal with Chinese online pharmacy Jianke
Pharmaforum
Pfizer
China
Jianke
Flag link:
Chi-Med, Innovent enter global cancer partnership
Chi-Med, Innovent enter global cancer partnership
BioCentury
Chi Med
Innovent Biologics
China
solid tumors
Flag link:
30 New Drugs from Foreign Countries Approved in China in Last 21 Months
30 New Drugs from Foreign Countries Approved in China in Last 21 Months
BioSpace
China
drug approvals
Flag link:

Pages